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SUMMARY
An analysis was undertaken to measure age-speciﬁc vaccine eﬀectiveness (VE) of 2010/11
trivalent seasonal inﬂuenza vaccine (TIV) and monovalent 2009 pandemic inﬂuenza vaccine
(PIV) administered in 2009/2010. The test-negative case-control study design was employed based
on patients consulting primary care. Overall TIV eﬀectiveness, adjusted for age and month,
against conﬁrmed inﬂuenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-speciﬁc
adjusted VE was 87% (95% CI 45–97) in<5-year-olds and 84% (95% CI 27–97) in 5- to
14-year-olds. Adjusted VE for PIV was only 28% (95% CIx6 to 51) overall and 72%
(95% CI 15–91) in<5-year-olds. For conﬁrmed inﬂuenza B infection, TIV eﬀectiveness was
57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate
protection against the main circulating strains in 2010/2011, with higher protection in children.
PIV administered during the previous season provided residual protection after 1 year,
particularly in the<5 years age group.
Key words : Inﬂuenza, inﬂuenza vaccines, vaccine-preventable diseases.
INTRODUCTION
The emergence of the 2009 pandemic inﬂuenza virus
led to the development and manufacture of a new
generation of monovalent inﬂuenza vaccines – some
of which employed new adjuvants. Many countries
implemented pandemic vaccine programmes targeted
at new risk groups, in particular children [1–3]. A
number of observational studies have since shown
the pandemic inﬂuenza vaccines (PIV) administered
during the pandemic had high levels of vaccine eﬀec-
tiveness (VE) against various end-points [4]. Early
mid-season analyses from 2010/11, including from the
UK, have suggested some residual protection from
the adjuvanted pandemic vaccine 12 months later in a
number of settings [5] as have some end-of-season
analyses [6].
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A number of countries are considering the potential
introduction of routine childhood seasonal inﬂuenza
vaccine programmes. Uncertainties continue regard-
ing the potential eﬀectiveness of seasonal inﬂuenza
vaccines in this particular age group – such infor-
mation will be critical to inform estimates of the
potential future impact and cost-eﬀectiveness of im-
plementing such vaccine programmes.
The 2010/11 inﬂuenza season was characterized
by the re-introduction of the normal, unadjuvanted
trivalent seasonal inﬂuenza vaccine (TIV) after the
2009 pandemic. The 2010/11 unadjuvanted TIV, as
recommended by WHO, included the inﬂuenza
A(H1N1)pdm 2009 strain [7], with the UK 2010/11
vaccination programme starting in autumn 2010 and
reaching a ﬁnal uptake of 50.4% in clinical at-risk
groups aged 6 months to 65 years.
The UK experienced intense inﬂuenza
A(H1N1)pdm 2009 transmission during the 2010/11
season, with later co-circulation of inﬂuenza B. This
provided the opportunity to undertake mid-season
estimate for VE using the established swab-negative
case-control approach [8, 9]. These mid-season esti-
mates against inﬂuenza A (H1N1)pdm 2009 infection
up to January 2011 have been published [5], demon-
strating an eﬀectiveness of 34% for monovalent vac-
cine only given in 2009/10, 46% for trivalent 2010/11
vaccine only and 63% if vaccinated with both vac-
cines.
This present study presents the end-of-season VE
for the 2010/11 TIV in preventing conﬁrmed inﬂuenza
A(H1N1)pdm 2009 and inﬂuenza B infection in
both children and adults. It also examines in further
detail the potential protection from vaccination
with monovalent A(H1N1)2009 vaccine administered
the previous season and ﬁnally the potential accuracy
of mid-season VE estimates.
METHODS
Study population and period
Data was derived from ﬁve primary-care inﬂuenza
sentinel surveillance schemes in England (two
schemes), Northern Ireland, Scotland and Wales.
Details of the Royal College of General Practitioners
(RCGP), Health Protection Agency (HPA) Regional
Microbiology Network (RMN), Public Health Wales
and Health Protection Scotland (HPS) swabbing
schemes have been presented previously [3]. The
Public Health Agency of Northern Ireland operated
a scheme with 37 practices in 2010/11, covering
11.6% of the registered population.
The study period ran from 1 September 2010 to
17 March 2011. Cases were deﬁned as persons pre-
senting during the study period in a participating
practice with an acute inﬂuenza-like illness (ILI)
who were swabbed and then tested positive for inﬂu-
enza A(H1N1)pdm 2009 or inﬂuenza B. ILI was de-
ﬁned as an acute respiratory illness with fever or
complaint of feverishness. Controls were individuals
presenting with ILI in the same period that were
swabbed and tested negative for inﬂuenza.
Individuals testing positive for other inﬂuenza A types
were dropped.
A standardized questionnaire collected demo-
graphic, clinical and epidemiological information
from cases and controls including date of birth, sex,
underlying clinical risk group, date of onset of res-
piratory illness, date of specimen and inﬂuenza vac-
cination status for 2010/11 and previous season with
vaccination dates was completed by the GP during the
patient consultation for their respiratory illness.
Vaccination data were derived from the patient’s
medical record.
Laboratory methods
Laboratory conﬁrmation was undertaken using real-
time polymerase chain reaction (RT–PCR) assays for
circulating inﬂuenza A viruses, inﬂuenza B viruses
and other respiratory viruses [10, 11]. Samples in
England were sent to the HPAMicrobiology Services,
Colindale (RCGP scheme) or one of the regional HPA
microbiology laboratories (RMN scheme). Samples
in Wales were sent to the Public Health Wales
Specialist Virology Centre and in Scotland to the
West of Scotland Specialist Virology Centre (HPS
scheme) for molecular testing. In Northern Ireland
samples were sent to the Regional Virus Laboratory,
Belfast.
Statistical methods
To assess VE based on monovalent H1N1 2009
vaccine and 2010/11 TIV status, a four-level variable
was deﬁned as previously [5] with the following
categories :
(1) unvaccinated in both years ;
(2) receipt of monovalent 2009 PIV in 2009/10 but
not in receipt of 2010/11 TIV;
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(3) receipt of either PIV in 2010/11 (provided to cer-
tain risk groups) or TIV in 2010/11 or both, but
not vaccinated in 2009/10;
(4) receipt of PIV in 2009/10 and TIV in 2010/11, or
received ﬁrst dose of PIV in 2009/10 and second
dose of PIV in 2010/11.
As numbers were low (ﬁve persons had two doses),
those that had received two doses of PIV in 2009/10
were not analysed separately from those who received
only one dose. Persons were deﬁned as vaccinated
if date of vaccination with 2010/11 TIV or PIV was
o14 days before onset of illness. Those in whom the
period between vaccination and onset of illness was
<14 days were excluded, as immunity is unknown.
When assessing VE of PIV or combination of PIV and
2010/11 TIV, only those with known vaccination
status were included. To assess VE of just 2010/11
TIV, individuals could still be included if PIV status
was not known. If the date of vaccination was missing,
as the 2010/11 campaign occurred before inﬂuenza
circulation, it was assumed that 2010/11 TIV vac-
cination waso14 days before onset date. For PIV, if
date of vaccination was missing, it was assumed the
person was vaccinated in 2009/10. If date of onset of
symptoms was missing then the date was assumed to
have been 4 days prior to the date the swab was taken
(the median interval based on the observed data).
Respiratory samples with a delay of >29 days be-
tween onset of illness and sample collection were ex-
cluded as the sensitivity of the PCR test is less eﬀective
for long intervals between onset and sampling. A
sensitivity analysis was also undertaken censoring at
7 days between onset of illness and sample collection.
VE was estimated as 1 – (odds ratio) using multi-
variable logistic regression models with inﬂuenza
A(H1N1)pdm 2009 or inﬂuenza B PCR results as
outcomes and seasonal or pandemic vaccination
status as the linear predictor. In the analyses evalu-
ating VE in preventing inﬂuenza A(H1N1)pdm 2009
infection, samples positive for inﬂuenza B were ex-
cluded and vice versa. Age (coded into ﬁve standard
age groups: <5, 5–14, 15–44, 45–64, o65 years),
gender, clinical risk group, surveillance scheme (HPS,
RCGP, RMN, NI, Wales) and date of sample collec-
tion (month) were investigated as potential con-
founding variables.
To assess the impact of missing vaccination history
(or date of vaccination) and to allow inclusion of the
risk group variable without dropping many individ-
uals, multiple imputation was used in a sensitivity
analysis. The analysis, which also imputed missing
data for gender and age, was performed using the
multiple imputations chained equation (MICE)
package in R (R version 2.13.0, R Foundation for
Statistical Computing, 2011). Additional variables,
which had no missing data, used in the imputation
were ﬂu virology status, month swab was collected
and surveillance scheme. All variables were included
as possible predictors of the missing data and logistic
regression was the model for gender and risk group,
proportional odds regression for age group, and poly-
tomous logistic regression for the combined seasonal/
pandemic vaccine status. Five separate imputation
datasets were imputed and the model estates com-
bined [12].
All other statistical analyses were performed in
Stata version 10 (StataCorp, USA).
RESULTS
A total of 7797 individuals were swabbed during the
study period. Thirty-nine were dropped as they were
positive for inﬂuenza H3 or inﬂuenza A but not in-
ﬂuenza A(H1N1)pdm 2009. Of the rest, 4418 (56.9%)
were collected from the RCGP scheme, 1902 (24.5%)
from the HPS scheme, 884 (11.4%) from the RMN
scheme, 190 (2.4%) from the Public Health Wales
Scheme and 364 (4.7%) from the PHA Northern
Ireland Scheme. Table 1 summarizes those individuals
excluded because of missing information. Vaccine
date was unknown for 25 individuals given TIV and
45 given PIV. Although date of onset was missing for
801 (10.3%) individuals, these were included with
onset date deﬁned as swab date minus 4 days.
The demographic and epidemiological character-
istics of cases and controls are summarized in Table 2.
A total of 848 individuals had received 2010/11 TIV
and 616 monovalent PIV. Whereas very few children
received 2010/11 TIV (14 aged<5 years and 27 aged
5–14 years).
Model ﬁtting for VE estimation
When estimating vaccine eﬀects, age group, gender,
time period and surveillance scheme were adjusted for
in a multivariable logistic regression model. Although
all these variables were signiﬁcantly associated with
having a positive swab, only age group and time
period were confounders for the vaccine eﬀects.
Risk group was missing for 2270 (29%) out of
7758 samples, and was therefore not included in the
Pandemic seasonal ﬂu vaccine eﬀectiveness 3
ﬁnal model. If risk group was included, or if multiple
imputation was used, the VE estimates remained
similar. Tables 3 and 4, as well as Figures 1–3 show
VE estimates against inﬂuenza A(H1N1)pdm 2009
and inﬂuenza B according to vaccination status and,
in the ﬁgures, by age group and scheme.
VE against inﬂuenza A(H1N1)pdm 2009 infection
The adjusted VE estimates against inﬂuenza
A(H1N1)pdm 2009 increased from 28% [95% conﬁ-
dence interval (CI)x6 to 51] for PIV only in 2009/10;
to 55% (95% CI 31–71) for vaccination only in
2010/11 mainly with 2010/11 TIV; to 60% (95% CI
39–73) if vaccinated in both seasons with PIV then
mainly with 2010/11 TIV (Table 3). Persons
who had received vaccination in both 2009/10 and
2010/11 or just in the 2010/11 season had a signiﬁ-
cantly higher VE compared to persons who received
PIV only in 2009/10 (Wald test P=0.012, 0.002 for
just 2010/11, both respectively). There was no diﬀer-
ence in VE between those vaccinated in both seasons
(PIV in 2009/10 and mainly TIV in 2010/11) and those
just vaccinated (mainly with TIV) in 2010/11
(P=0.58). The VE for 2010/11 TIV, irrespective
of previous PIV status, was 56% (95% CI 42–66)
(Table 4).
For 2010/11 TIV, there was no evidence VE dif-
fered signiﬁcantly by age group (P=0.16). VE was
87% (95% CI 45–97) in the<5 years age group and
84% (27–97) in the 5–14 years age group (Fig. 1a).
The point estimate was lower in older age groups
(Fig. 1a). For PIV there was no signiﬁcant diﬀerence
in VE estimates by age when using the ﬁve age groups
(P=0.12) but a diﬀerence was found when splitting
age as <5 and o5 years (P=0.04) (Fig. 2). This age
division was chosen due to the diﬀerent strategy for
the <5 years age group who were all recommended
the monovalent vaccine during 2009/10. This gave VE
estimates of 72% (95% CI 15–91) for the <5 years
age group and 10% (95% CIx36 to 41) for theo5
years age group. No signiﬁcant diﬀerence in VE was
observed by surveillance scheme (Fig. 3).
In a sensitivity analyses of VE against inﬂuenza
A(H1N1)pdm 2009, censoring samples taken>7 days
after symptom onset gave slightly higher VE estimates
with broader conﬁdence intervals : the adjusted VE
for those vaccinated in the previous season (2009/10)
was 39% (95% CI 5–61); for those vaccinated only in
the current season (2010/11) VE was 61% (95% CI
35–77) and for those vaccinated both seasons VE was
65% (95% CI 43–79). The VE for 2010/11 TIV ir-
respective of PIV status increased to 63% (95% CI
48–73). With multiple imputation, the results were
similar to those found without imputation, but did
allow adjustment for risk group: the imputed VE for
vaccination in both seasons was 59.0% (95% CI
36.4–73.6), which is similar to the VE estimate given
in Table 3.
Adjusting for month had a large eﬀect on VE for
those vaccinated in 2009/10, decreasing it from 53%
(crude) to 36% after adjustment.
Table 1. Inclusion and exclusion criteria of participants for specimens submitted, UK, 1 September 2010 to 17
March 2011
Criteria Excluded (n) Included (n)
1. Original participants 7758
Excluded as interval from onset to sampling>29 days 112
Remaining participants 7646
2. Analysis of monovalent H1N1 vaccine and 2010/11 TIV
Excluded as missing vaccination history 1203
Excluded as vaccinated 0–14 days before onset 70
Final remaining study participants 6373
Final for assessment of H1H1 (2009) 5372
Final for assessment of Flu B 4825
3. Analysis of 2010/11 TIV only
Excluded as missing vaccination history 438
Excluded as vaccinated 0–14 days before onset 87
Final remaining study participants 7121
Final for assessment of H1H1 (2009) 6004
Final for assessment of Flu B 5419
TIV, Trivalent seasonal inﬂuenza vaccine.
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Table 2. Details for pandemic inﬂuenza A(H1N1) 2009 and inﬂuenza B cases and controls, UK, September 2010 to
March 2011 (n=7758)
Controls, n (%)
(N=4730)
B cases, n (%)
(N=1211)
H1N1 (2009)
cases, n (%)
(N=1817)*
Age group (years)
<5 502 (10.6) 93 (7.7) 146 (8)
5–14 459 (9.7) 352 (29.1) 198 (10.9)
15–44 2161 (45.7) 577 (47.6) 1035 (57)
45–64 1148 (24.3) 154 (12.7) 406 (22.3)
o65 431 (9.1) 31 (2.6) 22 (1.2)
Missing 29 (0.6) 4 (0.3) 10 (0.6)
Sex
Male 1859 (39.3) 551 (45.5) 774 (42.6)
Female 2836 (60) 646 (53.3) 1027 (56.5)
Missing 35 (0.7) 14 (1.2) 16 (0.9)
Month of sample collection
September 123 (2.6) 1 (0.1) 0 (0)
October 534 (11.3) 9 (0.7) 34 (1.9)
November 661 (14) 56 (4.6) 73 (4)
December 1358 (28.7) 543 (44.8) 1356 (74.6)
January 1473 (31.1) 472 (39) 342 (18.8)
February 532 (11.2) 117 (9.7) 11 (0.6)
March 49 (1) 13 (1.1) 1 (0.1)
Surveillance scheme
RCGP 2771 (58.6) 643 (53.1) 1004 (55.3)
RMN 510 (10.8) 130 (10.7) 244 (13.4)
HPS 1135 (24) 359 (29.6) 408 (22.5)
Wales 85 (1.8) 43 (3.6) 62 (3.4)
Northern Ireland 229 (4.8) 36 (3) 99 (5.4)
Risk group
No 2626 (55.5) 750 (61.9) 1097 (60.4)
Yes 716 (15.1) 120 (9.9) 179 (9.9)
Missing 1388 (29.3) 341 (28.2) 541 (29.8)
Interval onset sampling (days)
0–1 531 (11.2) 139 (11.5) 260 (14.3)
2–4 1755 (37.1) 605 (50) 849 (46.7)
5–7 955 (20.2) 260 (21.5) 310 (17.1)
8–14 666 (14.1) 65 (5.4) 153 (8.4)
15–29 247 (5.2) 17 (1.4) 33 (1.8)
o29 93 (2) 7 (0.6) 12 (0.7)
Missing onset date# 483 (10.2) 118 (9.7) 200 (11)
Vaccination status (monovalent –
TIV combinations)
Unvaccinated 3223 (68.1) 917 (75.7) 1457 (80.2)
TIV only 240 (5.1) 22 (1.8) 31 (1.7)
TIV only (0–13 days) 32 (0.7) 2 (0.2) 9 (0.5)
Monovalent only 196 (4.1) 41 (3.4) 43 (2.4)
Both 236 (5) 26 (2.1) 31 (1.7)
Both (TIV 0–13 days) 24 (0.5) 2 (0.2) 4 (0.2)
Missing (either year) 779 (16.5) 201 (16.6) 242 (13.3)
Vaccination status (only considering TIV)
Unvaccinated 3767 (79.6) 1065 (87.9) 1637 (90.1)
Vaccinated 618 (13.1) 58 (4.8) 82 (4.5)
Vaccinated (0–13 days) 72 (1.5) 5 (0.4) 13 (0.7)
Missing 273 (5.8) 83 (6.9) 85 (4.7)
HPS, Health Protection Scotland; RCGP, Royal College of General Practitioners’ surveillance scheme; RMN, Health
Protection Agency (HPA) Regional Microbiology Network; TIV, trivalent seasonal inﬂuenza vaccine.
* Five cases positive by both H1N1 (2009) and inﬂuenza B are shown in this column.
# Missing onset date was calculated as 4 days prior to sample date.
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Table 3. Number and proportion of samples positive for inﬂuenza A(H1N1) 2009 and inﬂuenza B according to vaccination status and vaccine eﬀectiveness (VE)
(crude and adjusted*) estimates, UK, September 2010 to March 2011
Vaccination
status
No. H1N1
positive/N (%)
Crude VE
(95% CI)
Adjusted VE
(95% CI)
[5212 obs.]
No. ﬂu B
positive/N (%)
Crude VE
(95% CI)
Adjusted VE
(95% CI)
[4673 obs.]
Unvaccinated 1450/4610 (31.4%) — — 916/4076 (22.5%) — —
2009/10 monovalent 42/235 (17.9%) 53% (33–66) 28% (x6 to 51) 42/235 (17.9%) 25% (x6 to 47) x4% (x51 to 29)
2010/11 TIV only 30/267 (11.2%) 72% (59–81) 55% (31 to 71) 22/259 (8.5%) 68% (50 to 79) 56% (29 to 73)
Vaccinated in both seasons 31/260 (11.9%) 70% (53–80) 60% (39 to 73) 26/255 (10.2%) 61% (41 to 74) 53% (27 to 70)
CI, Conﬁdence interval ; TIV, trivalent seasonal inﬂuenza vaccine.
* Adjusted for age group, gender, time period and surveillance scheme.
Table 4. Number and proportion of samples positive for inﬂuenza A(H1N1) 2009 and inﬂuenza B according to 2010/11 TIV status and vaccine eﬀectiveness (VE)
(crude and adjusted*) estimates, UK, September 2010 to March 2011
Vaccination status
No. H1N1
positive/N (%)
Crude VE
(95% CI)
Adjusted VE
(95% CI)
[5820 obs.]
No. ﬂu B
positive/N (%)
Crude VE
(95% CI)
Adjusted VE
(95% CI)
[5244 obs.]
Unvaccinated 1626/5319 (30.6%) — — 1064/4757 (22.4%) — —
Vaccinated 81/685 (11.8%) 70% (61–76) 56% (42–66) 58/662 (8.8%) 67% (56–75) 57% (42–68)
CI, Conﬁdence interval ; TIV, trivalent seasonal inﬂuenza vaccine.
* Adjusted for age group, gender, time period and surveillance scheme.
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VE against inﬂuenza B infection
There was no evidence of any VE of PIV against
inﬂuenza B (Table 3). The VE analysis therefore only
considers 2010/11 vaccination status. The adjusted
VE was 57% (95% CI 42–68). Censoring samples
taken >7 days after symptom onset increased VE to
61% (95% CI 45–72).
There was no evidence VE varied by age group (no
signiﬁcant age–vaccine interaction, likelihood ratio
test, P=0.46). VE in the<5 years age group was 47%
(95% CI x337 to 93) and in 5–14 years age group
it was 75% (95% CI 32–91) (Fig. 1b). There was,
however, evidence that VE against B infection varied
for both surveillance scheme (Fig. 3) and strain (B/
Victoria and B/Yamagata). The majority (93%) of B
viruses circulating in England and Scotland in 2010/11
were of B/Victoria lineage. Of these B/Victoria iso-
lates, 7/268 cases had been vaccinated with 2010/11
TIV giving an adjusted VE of 78% (95% CI 51–91).
This compared to 3/15 B/Yamagata isolates, giving
an adjusted VE ofx34% (95% CIx448 to 68).
DISCUSSION
This observational study of inﬂuenza VE in the
UK has several key ﬁndings : ﬁrst, vaccination with
the 2010/11 TIV provided signiﬁcant protection
against laboratory-conﬁrmed infection for both in-
ﬂuenza A(H1N1)pdm 2009 and inﬂuenza B; second,
there was evidence of signiﬁcant protection with
2010/11 TIV for school children for both inﬂuenza
A(H1N1)pdm 2009 and B infections ; third, im-
munization with A(H1N1)2009 vaccine in 2009/10
followed by TIV in the 2010/11 season provided
similar protection against conﬁrmed inﬂuenza
A(H1N1)pdm 2009 infection to just receiving TIV
in 2010/11; fourth, protection against inﬂuenza
A(H1N1)pdm 2009 infection in 2010/11 following
vaccination with PIV 1 year previously in 2009/10 was
reduced, although for children aged<5 years VE was
maintained; ﬁfth, there was evidence of strain-speciﬁc
variation in VE for conﬁrmed inﬂuenza B infection
and ﬁnally the ﬁndings reinforce earlier published
mid-season estimates of VE [5].
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Fig. 1. Trivalent inﬂuenza vaccine eﬀectiveness 2010/11 against (a) H1N1 (2009) and (b) ﬂu B by age group UK, 2010–11.
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The swab-negative case-control study design is now
a well established approach to estimate inﬂuenza VE,
with several studies published on the methodology
[13, 14]. The potential limitations presented in this
paper have been outlined previously and relate
to convenience sampling of biological specimens
resulting in the potential for selection bias; missing
data items and lack of information on risk status [3].
Furthermore, for children aged<13 years the analy-
sis is based on having received one or more doses
of vaccines, as we were not able to disentangle those
who had received the recommended two doses from
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Fig. 3. Trivalent inﬂuenza vaccine eﬀectiveness 2010/11 against (a) inﬂuenza H1N1 (2009) and (b) ﬂu B by surveillance
scheme, 2010/11, UK. RCGP, Royal College of General Practitioners’ surveillance scheme; RMN, Health Protection Agency
(HPA) Regional Microbiology Network; HPS, Health Protection Scotland.
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Fig. 2. Pandemic inﬂuenza vaccine 2009 eﬀectiveness against H1N1 (2009) by age group UK, 2010–11.
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those who only received one dose. This could poten-
tially underestimate the VE of the recommended two-
dose schedule in this age group. We have presented
various sensitivity analyses to attempt to address the
potential impact on VE of missing data items. In ad-
dition, we have applied multiple imputation methods,
which have allowed us to adjust for risk status and
demonstrate that this was not an important con-
founding variable in this particular analysis.
This study conﬁrms that 2010/11 TIV was eﬀective
in protecting against both conﬁrmed inﬂuenza
A(H1N1)pdm 2009 and inﬂuenza B infection in
people consulting their GP with an acute respiratory
illness. This also conﬁrms published ﬁndings from
several settings including an earlier mid-season UK
analysis. These all demonstrated that the 2010/11
seasonal inﬂuenza vaccine provided moderate pro-
tection against inﬂuenza A(H1N1)pdm 2009 infection
[5, 15–18]. This VE is consistent with studies on the
eﬀectiveness of TIV in the pre-pandemic era, which
suggests that the vaccine is protective against the
circulating inﬂuenza strains [8, 9].
Among children we found that 2010/11 TIV was
signiﬁcantly eﬀective in both the <5 and 5–14 years
age groups in preventing inﬂuenza A(H1N1)pdm
2009 infection and in the 5–14 years age group only
for protecting against conﬁrmed inﬂuenza B infection.
Only a small number of studies have been published
on the eﬀectiveness of unadjuvanted seasonal inﬂu-
enza vaccines mainly in pre-school children [19–21]
and this current study provides further useful evi-
dence of the eﬀectiveness of unadjuvanted seasonal
TIV in children of all ages. This will be helpful
in informing decisions around possible intro-
duction of seasonal inﬂuenza vaccines into child-
hood – particularly for school-aged children.
Although recently published work has demon-
strated that the pandemic inﬂuenza A(H1N1) 2009
vaccine had good eﬀectiveness in 2009/10 in prevent-
ing conﬁrmed inﬂuenza A(H1N1)pdm 2009 infection
during the pandemic period in a wide range of geo-
graphical settings [2, 3], this present study indicates
that overall adjuvanted pandemic vaccine protection
does not last across the season to the following year.
This corroborates ﬁndings from our earlier mid-
season analysis in the UK [5] and Spain [17]. There
was, however, evidence in the current study that
PIV protection was maintained in children aged
<5 years. It is important to note that this particular
target group was broader compared to the older age
groups. In the UK all healthy children up to age 5
years, not just those in a clinical risk group, were
targeted with PIV in 2009/10 reaching an uptake of
23.6%. Furthermore, this part of the pandemic vac-
cine programme was delivered later in the 2009/10
season with most vaccine given in the spring of 2010
compared to those with an underlying clinical risk
factor aged <65 years, where the programme was
started in autumn 2009 and reached an uptake of
35.4%. Both these factors may explain why protec-
tion is maintained in this age group compared to older
age groups. Our study is also congruent with other
studies that have suggested pandemic inﬂuenza vac-
cine protection is lower in older children and adults in
the 2009/10 season [22], with others suggesting that
antibodies persist after 1 year in children after vacci-
nation with adjuvanted PIV [23].
The lower VE estimate against inﬂuenza B for the
Yamagata lineage strain is also of some interest. In
any season there may be several B variants within
the main inﬂuenza types/subtypes co-circulating. It
would be expected that the calculated VE would
vary dependent on how well the circulating strains
match the vaccine components. The trivalent seasonal
vaccine, however, contained only a single inﬂuenza B
strain in 2010/11; a B/Brisbane/60/2008-like virus.
During 2010/11, both Victoria lineage (B/Brisbane/
60/2008-like viruses) and Yamagata lineage (B/
Bangladesh/3333/2007-like viruses) inﬂuenza B
viruses were identiﬁed as circulating by molecular
analysis or antigenic typing. There is evidence of
some variation within the UK in the relative con-
tribution of each of these inﬂuenza B lineage strains;
in England 7% of inﬂuenza B viruses from any source
were characterized as B/Bangladesh/3333/2007-like,
while in Scotland although this ﬁgure was higher
(21%), it is based on a much smaller number of
samples submitted for molecular typing rather than
antigenic typing.
Although the earlier published mid-2010/11 season
UK estimates were reasonably accurate, one of the
main changes [5] in this end-of-season analysis is that
the possible dose–response relationship that persons
who received vaccination in both 2009/10 and 2010/11
seasons had a non-signiﬁcantly higher VE compared
to persons who received vaccine only 2009/10 is now
signiﬁcant in the current study. This highlights the
importance of annual re-vaccination with inﬂuenza
vaccine.
The current estimates are also now more precise
than the mid-season analysis, in particular for VE
against inﬂuenza B. Thus, although the mid-season
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estimate provided some important early ﬁndings, this
end-of-season study provides the deﬁnitive results and
also allows an age-speciﬁc analysis.
In conclusion, this end-of-season study provides
important evidence that the 2010/11 season’s TIV
provided protection against infection to both strains
of inﬂuenza circulating in the 2010/11 season [inﬂu-
enza A(H1N1)pdm 2009 and inﬂuenza B] in the UK.
In particular, the study provides evidence of TIV
eﬀectiveness in school-aged children, which will be
an important ﬁnding in consideration of potential
extension of the national programme to children. The
ﬁndings also provide evidence that PIV protection
wanes after 1 year except for those aged <5 years.
The study reinforces the recommendation that annual
re-immunization of target groups is required regard-
less of vaccination the previous season (including
those vaccinated with an adjuvanted vaccine).
Furthermore, the study conﬁrms the potential value
of undertaking a mid-season analysis to provide an
early estimate of protection. This can provide key in-
formation to assist decision-making, e.g. the WHO
vaccine strain selection for the following season.
ACKNOWLEDGEMENTS
We are grateful to the many primary-care physicians
in England, Wales, Northern Ireland and Scotland
who supplied clinical information on their patients ; to
the staﬀ of the HPA Respiratory Virus Unit, the HPA
regional microbiology laboratories, Public Health
Wales Specialist Virology Centre, the West of
Scotland Specialist Virology Centre and the Regional
Virus Laboratory, Belfast who undertook analysis of
specimens. We thank the staﬀ of the Health
Protection Agency, RCGP, Public Health Wales,
Public Health Agency Northern Ireland and Health
Protection Scotland teams who coordinate the GP
schemes, in particular Joy Field from the HPA;
Catherine Frew and Rory Gunson from WoSSVC
and Arlene Reynolds, Rachael Darroch and Drew
Palmer from HPS for overseeing data collection.
This work has been undertaken as part of a
European Centre for Disease Control and Prevention
(ECDC)-funded project ‘I-MOVE’, which is coor-
dinated by Epi-Concept (http://www.epiconcept.fr/).
DECLARATION OF INTEREST
D. M. Fleming has received funding to attend inﬂuenza-
related meetings and has received consultancy fees from
inﬂuenza vaccine manufacturers who might have an
interest in the submitted work in the previous 3 years. In
addition, The Virus Reference Department of the
Health Protection Agency receives funding from a var-
iety of vaccine manufacturers who might have an in-
terest in the submitted work.
REFERENCES
1. Wichmann O, et al. Pandemic inﬂuenza A(H1N1)
2009 breakthrough infections and estimates of vaccine
eﬀectiveness in Germany 2009–2010. Eurosurveillance
2010; 15.
2. Valenciano M, et al. Estimates of pandemic inﬂuenza
vaccine eﬀectiveness in Europe, 2009–2010: results
of inﬂuenza monitoring vaccine eﬀectiveness in Europe
(I-MOVE) multicentre case-control study. PLoS
Medicine 2011; 8 : e1000388.
3. Hardelid P, et al. Eﬀectiveness of pandemic and seaso-
nal inﬂuenza vaccine in preventing pandemic inﬂuenza
A(H1N1)2009 infection in England and Scotland
2009–2010. Eurosurveillance 2011; 16.
4. Andrews N, et al. Age-speciﬁc eﬀectiveness of an oil-
in-water adjuvanted pandemic (H1N1) 2009 vaccine
against conﬁrmed infection in high risk groups in
England. Journal of Infectious Diseases 2011; 203 :
32–39.
5. Pebody R, et al. Eﬀectiveness of seasonal 2010/11
and pandemic inﬂuenza A(H1N1)2009 vaccines in
preventing inﬂuenza infection in the United Kingdom:
mid-season analysis 2010/11. Eurosurveillance 2011; 16.
6. Jimenez-Jorge S, et al. Eﬀectiveness of the 2010–11
seasonal trivalent inﬂuenza vaccine in Spain : cycEVA
study. Vaccine 2012; 30 : 3595–3602.
7. Department of Health. Seasonal inﬂuenza vaccine up-
take amongst GP patient groups in England, 2010/11
(http://www.dh.gov.uk/prod_consum_dh/groups/dh_
digitalassets/documents/digitalasset/dh_129856.pdf).
8. Skowronski DM, et al. Estimating vaccine eﬀectiveness
against laboratory-conﬁrmed inﬂuenza using a sentinel
physician network: results from the 2005–2006 season
of dual A and B vaccine mismatch in Canada. Vaccine
2007; 25 : 2842–2851.
9. Fleming DM, et al. Estimating Inﬂuenza vaccine eﬀec-
tiveness using routinely collected laboratory data.
Journal of Epidemiology and Community Health 2010;
64 : 1062–1067.
10. Ellis J, et al. Evaluation of four real-time PCR
assays for detection of inﬂuenza A(H1N1)v viruses.
Eurosurveillance 2009; 14 : pii=19230.
11. Gunson R, et al. Development of a multiplex real-time
RT-PCR that allows universal detection of inﬂuenza A
viruses and simultaneous typing of inﬂuenza A/H1N1/
2009 virus. Journal of Virological Methods 2010; 163 :
258–261.
12. van Buuren S, Groothuis-Oudshoorn K. mice : multi-
variate imputation by chained equations. Journal of
Statistical Software 2011; 45 : 1–67.
10 R. G. Pebody and others
13. Ferdinands JM, et al. Inﬂuenza vaccination status is
not associated with inﬂuenza testing among children :
implications for observational studies of vaccine eﬀec-
tiveness. Vaccine 2011; 29 : 1935–1940.
14. Orenstein EW, et al. Methodologic issues regarding
the use of three observational study designs to assess
inﬂuenza vaccine eﬀectiveness. International Journal of
Epidemiology 2007; 36 : 623–631.
15. Kissling E, Valenciano M. Early estimates of seasonal
inﬂuenza vaccine eﬀectiveness in Europe, 2010/11 :
I-MOVE, a multicentre case-control study. Euro-
surveillance 2011; 16.
16. Fielding JE, et al. Eﬀectiveness of seasonal inﬂuenza
vaccine against pandemic (H1N1) 2009 virus, Australia,
2010. Emerging Infectious Diseases 2011; 17 : 1181–
1187.
17. Castilla J, et al. Eﬀectiveness of trivalent seasonal
and monovalent inﬂuenza A(H1N1)2009 vaccines in
population with major chronic conditions of Navarre,
Spain: 2010/11 mid-season analysis. Eurosurveillance
2011; 16.
18. Skowronski DM, et al. A sentinel platform to evaluate
inﬂuenza vaccine eﬀectiveness and new variant circu-
lation, Canada 2010–11 season. Clinical Infectious
Diseases. Published online : 21 May 2012. PMID no. :
22539661.
19. Szilagyi PG, et al. Inﬂuenza vaccine eﬀectiveness
among children 6 to 59 months of age during 2
inﬂuenza seasons : a case-cohort study. Archives of
Pediatrics & Adolescent Medicine 2008 ; 162 : 943–951.
20. Heinonen S, et al. Eﬀectiveness of inactivated inﬂuenza
vaccine in children aged 9 months to 3 years : an ob-
servational cohort study. Lancet Infectious Diseases
2011; 11 : 23–29.
21. Eisenberg KW, et al. Vaccine eﬀectiveness against
laboratory-conﬁrmed inﬂuenza in children 6 to 59
months of age during the 2003–2004 and 2004–2005
inﬂuenza seasons. Pediatrics 2008; 122 : 911–919.
22. Griﬃn MR, et al. Eﬀectiveness of non-adjuvanted
pandemic inﬂuenza A vaccines for preventing
pandemic inﬂuenza acute respiratory illness visits
in 4 U.S. communities. PLoS One 2011; 6 : e23085.
23. Walker WT, et al. H1N1 antibody persistence 1 year
after immunization with an adjuvanted or whole-
virion pandemic vaccine and immunogenicity and
reactogenicity of subsequent seasonal inﬂuenza vac-
cine : a multicenter follow-on study. Clinical Infectious
Diseases 2012; 54 : 661–669.
Pandemic seasonal ﬂu vaccine eﬀectiveness 11
